Minneapolis, MN, Oct. 24, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company
developing a proprietary platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP)
marketplace, today announced that the Company has engaged Quintain Project Solutions LLC as the manufacturing project management
leader for the PURE EP(TM) System.
Philadelphia-based Quintain Project Solutions LLC is a boutique consulting firm focused on providing strategic project
management, risk management, process improvement, cost management, contract compliance and forensic project analysis to companies
across several industries. The company’s Principal, Mark D. Steele, PE, CCP, an author of “Projects On Purpose”, is an
experienced engineer and project management consultant with over 25 years of experience. Throughout his career, Mr. Steele has
assisted clients with complex, critical projects ranging in size from a few million to a few billion dollars.
With proven project management expertise, Mr. Steele will lead the BioSig PURE EP manufacturing project team through the final
testing, production, regulatory clearance and, finally, into production of initial commercial units.
“We are excited to be working with BioSig and its manufacturing partner, Minnetronix, during this critical time in preparation
for FDA submission and commercialization. We will be assisting the Company every step of the way to ensure project success,”
commented Mr. Steele.
“Mark has impressed everyone on our team with his ability to tackle a project, quickly identifying critical points that will
allow him to effectively drive PURE EP product delivery to a successful completion. Quintain will be the point of interface for the
Company and our contract manufacturer, Minnetronix, taking on the PURE EP verification and validation testing process. These test
results provide critical data sets for the Company’s FDA submission,” said Kenneth Londoner, Chairman & Chief Executive Officer of
BioSig Technologies, Inc.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4.6 billion
electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of
Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has
been developed to address an unmet need in a large and growing market.
The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists
in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main
goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial
Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA
510(k) clearance for the PURE EP System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed
information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in
the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s
website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
Contact: Natasha Russkina BioSig Technologies, Inc. VP Business Development & Corporate Finance nrusskina@biosigtech.com +41 (0) 76 823 7527
